DNA amplification tests at universal pre-admission screening with enhanced precaution strategies for asymptomatic patients with COVID-19.

Admission COVID-19 NAATs Universal screening

Journal

IJID regions
ISSN: 2772-7076
Titre abrégé: IJID Reg
Pays: England
ID NLM: 9918418183106676

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 11 10 2022
revised: 22 12 2022
accepted: 23 12 2022
pubmed: 10 1 2023
medline: 10 1 2023
entrez: 9 1 2023
Statut: ppublish

Résumé

To analyse the effect of hospital pre-admission screening and enhanced precaution strategies on the transmission of severe acute respiratory syndrome coronavirus-2. This retrospective cohort study was conducted over 17 months from 11 May 2020 to 30 September 2021 at a large hospital in Tokyo. Universal DNA amplification tests were conducted during pre-admission screening, and enhanced precaution strategies were implemented for all patients with negative admission tests. The primary outcome was the occurrence of symptomatic coronavirus disease 2019 (COVID-19) in patients after admission. The secondary outcomes were time-series analyses of monthly positive admission test numbers, positive rates, clinical features in positive cases, and clinically confirmed nosocomial transmission. In total, 32,081 patients were screened pre-admission (29,556 asymptomatic patients and 2525 symptomatic patients). Of the asymptomatic patients, 0.11% ( Pre-admission test screening was effective in identifying asymptomatic cases of COVID-19. This allowed administrators to quarantine patients or delay hospital admission. The combination of testing and enhanced precaution strategies for asymptomatic cases of COVID-19 may minimize nosocomial transmission.

Identifiants

pubmed: 36618878
doi: 10.1016/j.ijregi.2022.12.010
pii: S2772-7076(22)00157-6
pmc: PMC9803604
doi:

Types de publication

Journal Article

Langues

eng

Pagination

6-10

Informations de copyright

© 2022 The Author(s).

Déclaration de conflit d'intérêts

None declared.

Références

J Hosp Infect. 2021 Aug;114:167-170
pubmed: 33940091
J Perinat Med. 2020 Nov 26;48(9):981-984
pubmed: 32681783
Clin Infect Dis. 2021 Nov 2;73(9):e3127-e3129
pubmed: 33570097
JAMA Netw Open. 2021 Jan 4;4(1):e2035057
pubmed: 33410879
Clin Microbiol Infect. 2022 Feb;28(2):178-189
pubmed: 34757116
Clin Microbiol Infect. 2021 Apr;27(4):658-659
pubmed: 33221431
J Clin Virol. 2021 Sep;142:104915
pubmed: 34315009
Viruses. 2021 Apr 30;13(5):
pubmed: 33946201
Emerg Infect Dis. 2021 Feb;27(2):404-410
pubmed: 33395382
Int J Gynaecol Obstet. 2020 Aug;150(2):268-269
pubmed: 32496574
J Bone Joint Surg Am. 2020 Aug 19;102(16):1379-1388
pubmed: 32516279
Infect Control Hosp Epidemiol. 2020 Sep;41(9):1075-1076
pubmed: 32456720
Clin Infect Dis. 2021 Nov 2;73(9):e3013-e3018
pubmed: 33090210
Birth. 2021 Mar;48(1):96-103
pubmed: 33263210
Lancet Infect Dis. 2020 Dec;20(12):1381-1389
pubmed: 32822577
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):472-476
pubmed: 32298249
Emerg Infect Dis. 2021 Apr;27(4):
pubmed: 33600301

Auteurs

Itaru Nakamura (I)

Department of Infection Prevention and Control, Tokyo Medical University Hospital, Tokyo, Japan.

Yusuke Watanabe (Y)

Department of Infection Prevention and Control, Tokyo Medical University Hospital, Tokyo, Japan.

Hiroaki Fujita (H)

Department of Infection Prevention and Control, Tokyo Medical University Hospital, Tokyo, Japan.

Takehito Kobayashi (T)

Department of Infection Prevention and Control, Tokyo Medical University Hospital, Tokyo, Japan.

Hidehiro Watanabe (H)

Department of Infection Prevention and Control, Tokyo Medical University Hospital, Tokyo, Japan.

Takao Itoi (T)

Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan.

Classifications MeSH